An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : SAR302503 (TG101348)
Phase: Phase 1/Phase 2
Ages Eligible For Study:
- Completion of MF-TG101348-001 study - Diagnosis of myelofibrosis - At least 18 years of age